All the content of the library is provided from Mayo Clinic in English.
As a member of the Mayo Clinic Care Network, RSPP has special access to Mayo Clinic knowledge and resources.
Feminizing hormone therapy is used to make physical changes in the body that are caused by female hormones during puberty. Those changes are called secondary sex characteristics. This hormone therapy can help better align the body with a person's gender identity. Feminizing hormone therapy also is called gender-affirming hormone therapy.
Feminizing hormone therapy involves taking medicine to block the action of the hormone testosterone. It also includes taking the hormone estrogen. Estrogen lowers the amount of testosterone the body makes. It also triggers the development of feminine secondary sex characteristics. Feminizing hormone therapy can be done alone or along with feminizing surgery.
Feminizing hormone therapy can affect fertility and sexual function, and it might lead to health problems. Talk with your healthcare professional about the risks and benefits.
Feminizing hormone therapy is used to change the body's hormone levels. Those hormone changes trigger physical changes that help better align the body with a person's gender identity.
In some cases, people seeking feminizing hormone therapy experience discomfort or distress because their gender identity differs from their sex assigned at birth or from their sex-related physical characteristics. This condition is called gender dysphoria.
Feminizing hormone therapy can:
Your healthcare professional might advise against feminizing hormone therapy if you:
Research has found that feminizing hormone therapy can be safe and effective when delivered by a healthcare professional with expertise in transgender care. Talk to a member of your care team about questions or concerns you have regarding the changes that will or will not happen in your body as a result of feminizing hormone therapy.
Feminizing hormone therapy may lead to other health conditions called complications. Complications of feminizing hormone therapy can include:
Evidence suggests that people who take feminizing hormone therapy may have a higher risk of breast cancer when compared to cisgender men — men whose gender identity aligns with their sex assigned at birth. But the risk is not greater than that of cisgender women — women whose gender identity aligns with their sex assigned at birth.
To minimize risk, the goal for people taking feminizing hormone therapy is to keep hormone levels in the range that's typical for cisgender women.
Feminizing hormone therapy may limit fertility. If possible, it's best to make decisions about fertility before starting treatment. The risk of permanent infertility increases with long-term use of hormones. That is particularly true if hormone therapy is started before puberty begins. Even after stopping hormone therapy, the testicles might not recover enough to ensure conception without infertility treatment.
If you want to have biological children, talk to your healthcare professional about freezing sperm before you start feminizing hormone therapy. That procedure is called sperm cryopreservation.
Before you start feminizing hormone therapy, your healthcare professional assesses your health. This helps address any medical conditions that might affect your treatment. The evaluation may include:
You also might have a behavioral health evaluation by a healthcare professional with expertise in transgender health. The evaluation may assess:
People younger than age 18, along with a parent or guardian, should see a healthcare professional and a behavioral health professional with expertise in pediatric transgender health to talk about the risks and benefits of hormone therapy and gender transitioning in that age group.
You should start feminizing hormone therapy only after you've talked about the risks and benefits, as well as all treatment options available to you, with a healthcare professional who has expertise in transgender care. Make sure that you understand what will happen and get answers to any questions you may have before you begin hormone therapy.
Feminizing hormone therapy typically begins by taking the medicine spironolactone (Aldactone). It blocks male sex hormone receptors — also called androgen receptors. This slows or stops changes in the body that usually happen due to testosterone.
About 4 to 8 weeks after you start taking spironolactone, you begin taking estrogen. This lowers the amount of testosterone the body makes. And it triggers physical changes in the body that are caused by female hormones during puberty.
Estrogen can be taken several ways. They include a pill and a shot. There also are several forms of estrogen that are applied to the skin, including a cream, gel, spray and patch.
It is best not to take estrogen as a pill if you have a personal or family history of blood clots in a deep vein or in the lungs, a condition called venous thrombosis.
Another choice for feminizing hormone therapy is to take gonadotropin-releasing hormone (Gn-RH) analogs. They lower the amount of testosterone that the body makes and might allow you to take lower doses of estrogen without taking spironolactone. The disadvantage is that Gn-RH analogs usually are more expensive.
After you begin feminizing hormone therapy, you'll notice the following changes in your body over time:
Some of the physical changes caused by feminizing hormone therapy can be reversed if you stop taking it. Others, such as breast development, cannot be reversed.
While on feminizing hormone therapy, you meet regularly with your healthcare professional to:
You also need routine preventive care. Depending on your situation, this may include: